10:30 às 13:30
Reunião dos grupos cooperativos (LACOG, GBECAM, EVA, GBOT, GTG). Apenas para convidados

13:50 às 14:00
ABERTURA
Abertura
Carlos Sampaio e Aknar Freire de Carvalho Calabrich (BA)

14:00 às 15:15
MÓDULO I – GINECOLÓGICO
Moderadora: Aknar Freire de Carvalho Calabrich (BA)
Abstract ID: 5500 - Title: A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial
Palestrante: Daniela de Freitas (SP)

Palestrante: Angelica Nogueira Rodrigues (MG)

Abstract ID: 5506 - Title: Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial
Palestrante: Aknar Freire de Carvalho Calabrich (BA)

Abstract ID: 5508 - Title: EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study
Palestrante: Maria Del Pilar Estevez Diz (SP)

Discussão
Practice Changing
Palestrante: Angelica Nogueira Rodrigues (MG)

15:20 às 16:30
MÓDULO II – MELANOMA
Moderador: Sérgio Jobim de Azevedo (RS)
Abstract ID: 9500 - Title: Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs)
Palestrante: Robson Ferrigno (SP)

Abstract ID: 9501 - Title: Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
Palestrante: Andréia Cristina de Melo (RJ)

Abstract ID: 9503 - Title: Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
Palestrante: Sérgio Jobim de Azevedo (RS)

Abstract ID: 9507 - Title: Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.
Palestrante: Rodrigo Antonio Vieira Guedes (BA)

Discussão
Practice Changing
Palestrante: Andréia Cristina de Melo (RJ)

16:30 às 17:00
COFFEE BREAK
17:00 as 17:15 PROJETO CURA - Entrega do Prêmio Renata Thormann Prociánov

17:15 às 19:00 MÓDULO III – PULMÃO

Moderador: Artur Katz (SP)

Abstract ID: 8502 - Title: Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC)
Palestrante: Samira da Silva Mascarenhas (BA)

Abstract ID: 8503 - Title: Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3)
Palestrante: Clarissa Serodio da Rocha Baldotto (RJ)

Abstract ID: 8504 - Title: Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study
Palestrante: William Nassib William Júnior (SP)

Abstract ID: 8506 - Title: Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial
Palestrante: Vladimir Cláudio Cordeiro de Lima (SP)

Abstract ID: 9000 - Title: RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC)
Palestrante: Carolina Kawamura Haddad (SP)

Abstract ID: 9001 - Title: Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C)
Palestrante: Artur Katz (SP)

Abstract ID: 9002 - Title: ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC
Palestrante: Ana Caroline Zimmer Gelatti (RS)

Discussão

Practice Changing
Palestrante: William Nassib William Júnior (SP)
08:00 às 09:30  MÓDULO IV – GENITOURINÁRIO

Moderador: Fernando Cotait Maluf (SP)

Abstract ID: 4504 - Title: Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182
Palestrante: Andrey Soares (SP)

Abstract ID: 4503 - Title: CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma
Palestrante: Augusto Mota (BA)

Abstract ID: 4500 - Title: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study
Palestrante: Igor A Protzner Morbeck (DF)

Abstract ID: 5006 - Title: First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
Palestrante: Diogo Assed Bastos (SP)

Abstract ID: 5008 - Title: Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)
Palestrante: Daniel Herchenhorn (RJ)

Abstract ID: LBA2 - Title: Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial
Palestrante: Fernando Cotait Maluf (SP)

Discussão

Practice Changing
Palestrante: Diogo Assed Bastos (SP)

09:30 às 10:15  SIMPÓSIO SATÉLITE ASTRAZENECA

Manutenção de Lynparza em Pacientes com Câncer de Pâncreas e mutação de BRCA – POLO Trial
Palestrante: Diogo Bugano Diniz Gomes

10:15 às 10:30  COFFEE BREAK
10:30 às 12:10 MÓDULO V – GASTROINTESTINAL

Moderador: Gustavo dos Santos Fernandes (DF)
Abstract ID: 3501 - Title: Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colorectal cancer (CC)
Palestrante: Fernanda Cunha Capareli (SP)

Abstract ID: 3504 - Title: FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer
Palestrante: Gabriel Prolla (RS)

Abstract LBA4007: Title: Pembrolizumab with or without chemotherapy versus chemotherapy in advanced G/GEJ adenocarcinoma: the phase 3, KEYNOTE-062 study
Palestrante: Túlio Pfiffer (SP)

Abstract ID: LBA4 - Title: Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial
Palestrante: Rui Fernando Weschenfelder (RS)

Abstract ID: 4000 - Title: APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma
Palestrante: Jorge Sabbaga (SP)

Abstract ID: 4003 - Title: ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Palestrante: Rachel Riechelmann (SP)

Discussão
Practice Changing
Palestrante: Anelisa K. Coutinho (BA)

12:10 às 13:00 SIMPÓSIO SATÉLITE NOVARTIS

Reimagine Oncology
Chairman: Fernando Cotait Maluf (SP)
Speakers: Rodrigo Munhoz (SP)
Carlos Barrios (RS)
Rui Fernando Weschenfelder (RS)
André Sasse (SP)

13:00 às 14:00 MÓDULO VI - CABEÇA E PESCOÇO

Moderadora: Aline Lauda Freitas Chaves (MG)

Abstract ID: 6000 - Title: Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Palestrante: Aline Lauda Freitas Chaves (MG)

Abstract ID: 6002 - Title: TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Palestrante: Pedro Rafael Martins de Marchi (SP)
Abstract ID: 6003 - Title: Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial
Palestrante: Gilberto de Castro Junior (SP)

Discussão
Practice Changing
Palestrante: Gilberto de Castro Junior (SP)

14:00 às 14:45 SIMPÓSIO SATÉLITE LIBBS

14:45 às 16:30 MÓDULO VII – MAMA

Moderador: Rafael Kaliks (SP)
Abstract ID: 503 - Title: Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx
Palestrante: Andréa Gadêlha Guimarães (SP)

Abstract ID: 504 - Title: Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM)
Palestrante: Gilberto Amorim (RJ)

Abstract ID: 1000 - Title: SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)
Palestrante: José Bines (RJ)

Abstract ID: 1002 - Title: Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with = 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial
Palestrante: Marcelo Rocha de Sousa Cruz (SP)

Abstract ID: 1003 - Title: IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC)
Palestrante: Tomás Reinert (RS)

Abstract ID: LBA1008 - Title: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results
Palestrante: Gustavo Werutsky (RS)

Discussão
Practice Changing
Palestrante: Max Mano (SP)

16:30 às 17:15 SIMPÓSIO SATÉLITE ROCHE

Impacto na prática clínica da imunoterapia em TNBC e Teste diagnóstico PD-L1 em TNBC
Palestrantes: Carlos Barrios e Fernando Soares

17:15 ENCERRAMENTO

Palestrante: Gustavo Werutsky (RS)